ClinicalTrials.gg
RecruitingNCT06647069Updated Oct 21, 2026

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

A Phase 1 interventional study of SAR448501 in Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), sponsored by Sanofi. Recruiting at 8 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 21, 2026First site in Georgia2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies in Lupus Erythematosus, Systemic with a site in South Africa — 9 open to participants now, 17 under way, 10 of them phase 3. Lupus Erythematosus, Systemic · South Africa.

Planned enrollment
33rd of 37
62 · median 423
Started
2025
with 1 other
Phase 1
3 of 37
1 open now
Primary completion
2029-06
later than 13 of 16 live
Registered
31st of 37
by date

Among the 37 studies in Lupus Erythematosus, Systemic with a site in South Africa, this one is the 33rd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 13 of the 16 other live ones, and was the 31st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 37 studies in Lupus Erythematosus, Systemic with a site in South Africa are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Lupus Erythematosus, Systemic with a site in South Africa, or all of them as a file.
02

Study summary

This is an open-label, multi-ascending dose (MAD) phase 1 study, with dose expansion at selected doses, in adult patients with select autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The purpose of the study is to identify possible optimal dose(s) by assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary clinical response of SAR448501/DR-0201.

The study duration per participant will be a minimum of approximately 13 months, including a screening period of up to 28 days, a treatment period of 71 days, and a follow-up period of 42 weeks. If necessary, participants will continue to have visits after End of Study (EOS) every 4 weeks until peripheral blood B cells return to at least 80% of either the lower limit of normal (LLN) or the participant's baseline value.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SLE and/or RA. American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria should be used.
  • during the study intervention period and for at least 140 days after the last administration of study intervention: Male participants must agree to refrain from donating or cryopreserving sperm, and either be abstinent or use contraception/barrier. Female participants must use of a highly effective contraceptive measure for all females of . Females of childbearing potential need to have a negative serum pregnancy test within 7 days prior to the first dose.
  • Specific to Systemic Lupus Erythematosus (SLE):

    • Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score ≥8 at screening with at least 4 points from clinical features at screening.
    • At least 1 British Isles Lupus Assessment (BILAG) A score or 1 BILAG B score at screening
    • Positive ANA (titer ≥1:80) as documented in the participant's medical history
    • Positive for any of the following as documented in the participant's medical history: antidsDNA, anti-Ro (anti-SS-A), anti-La (anti-SS-B), or anti-Sm antibodies
    • Inadequate response to systemic and to at least 1 therapy other than antimalarials for at least 12 weeks including: cyclophosphamide, mycophenolate mofetil or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus, or voclosporin.
  • Specific to Rheumatoid Arthritis (RA):

    -- Moderate-to-severe disease activity as defined by a 28-joint disease activity score using C reactive protein (DAS28-CRP) >3.2 at screening.

  • Inadequate response or intolerance to at least 2 disease-modifying antirheumatic drugs (DMARDs, at least 1 biologic [bDMARD] or targeted synthetic [tsDMARD]) after a minimum of 12 weeks treatment duration.
  • At least 6 tender joints at screening.
  • At least 6 swollen joints at screening.
  • Methotrexate (MTX) for at least 12 consecutive weeks, and at a stable dose of ≤25 mg/week oral or SC since at least 4 weeks prior to randomization, OR - in case of MTX intolerance - conventional DMARDs at a stable dose for at least 28 days.
  • If taking MTX, compliant with folic acid 1 mg daily or 5 mg weekly or greater in combination with MTX.

Exclusion criteria

Exclusion Criteria:

  • Severe manifestation of the selected rheumatic diseases under study that could impact participant safety, or is likely to require interventions that will affect drug PD.
  • Receipt of super-high potency (eg, clobetasol propionate, betamethasone dipropionate) or high potency (eg, fluocinonide, methylprednisolone aceponate) topical within 28 days prior to screening, had dose changes in other topical corticosteroids within 14 days prior to Day 1, or had dose changes in nonsteroidal topical within 28 days prior to Day 1.
  • Received dose changes of mycophenolate mofetil, methotrexate, leflunomide, calcineurin inhibitors, JAK inhibitors, or azathioprine within 28 days prior to Day 1.
  • Receipt of any of the following medications within 6 months of Day 1: cyclophosphamide, leflunomide >20 mg/day, abatacept.
  • Receipt of any mAb or experimental immunomodulator within 28 days or 5 published half-lives prior to Day 1, whichever is longer.
  • Receipt of rituximab or other B cell depleting biologics within 6 months of Day 1.
  • Receipt of rituximab or other B cell depleting biologics without return of CD19 or CD20 count to above the LLN.
  • Receipt of alemtuzumab, bone marrow transplantation, stem cell transplantation, total lymphoid irradiation, CAR-T or T cell vaccination therapy.
  • Known history of a primary immunodeficiency or an underlying condition such as known (HIV) infection, positive result for HIV infection, splenectomy, or any underlying condition that predisposes the participant to infection.
  • History of a reaction or anaphylaxis to a previous mAb or human immunoglobulin therapy.
  • Active infection or a history of serious infections as defined in the protocol.
  • Surgery within 28 days prior to Day 1.
  • 12-lead parameters after 10 minutes resting in supine position NOT in the defined normal ranges.
  • Evidence of significant, uncontrolled concurrent disease that could affect compliance with the study (eg, ).
  • Diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of basal cell or squamous epithelial carcinomas of the skin that have been resected or cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline.
  • High dose of antimalarial or a change in dose within 28 days prior to Day 1.
  • Receipt of systemic corticosteroids >20 mg/day (prednisone or equivalent) or had dose changes of systemic corticosteroids within 28 days prior to Day 1.
  • Documented liver disease including documented diagnosis of cirrhosis.
  • Participants with a history of hypercoagulation event or thrombosis (such as venous thromboembolism, pulmonary embolism, or stroke), or participants who have known hypercoagulation risk factors (including antiphospholipid syndrome), or participants currently on anticoagulation will be excluded.
  • Specific to SLE:

    • Active severe or unstable neuropsychiatric SLE including but not limited to seizures, psychosis, acute confusional state, transverse myelitis, central nervous system vasculitis and optic neuritis at screening.
    • Known -proven diagnosis of lupus nephritis (any class) or otherwise unexplained proteinuria (0.5g protein/24h; or urine protein/creatinine ratio >0.5g/g) at screening.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    SAR448501 dose escalation

    SAR448501 will be administered for up to 71 days. Different cohorts with up to 7 dose levels will be included.

    Drug: SAR448501

Interventions

  • Bispecific antibody

    Also known as: DR-0201

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Baseline to Week 52 (End of Study (EOS))

  2. Incidence of potentially clinically significant abnormalities (PCSAs)

    PCSAs include laboratory parameters; vital signs; and ECG parameters including heart rate, PR, QRS, QT, QTcF.

    Time frame: Baseline to Week 52 (EOS)

Secondary outcomes

  1. Assessment of pharmacokinetic (PK) parameters: AUC0-t

    Area under the plasma concentration versus time curve calculated using the trapezoidal method during a dosing interval (t)

    Time frame: Baseline to Week 20

  2. Assessment of pharmacokinetic (PK) parameters: Cmax

    Maximum observed plasma concentration

    Time frame: Baseline to Week 20

  3. Assessment of pharmacokinetic (PK) parameters: Ctrough

    Concentration observed before treatment administration during repeated dosing

    Time frame: Baseline to Week 20

  4. Incidence of anti-drug antibodies (ADAs)

    Incidence of ADAs against SAR448501/DR-0201

    Time frame: Baseline to Week 16

07

Study locations

8 of 8 sites recruiting
  • Investigational Site Number : 001-201
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Investigational Site Number : 001-401
    Sarajevo, 71000, Bosnia and Herzegovina
    Recruiting
  • Investigational Site Number : 268-003
    Tbilisi, 0141, Georgia
    Recruiting
  • Investigational Site Number : 268-001
    Tbilisi, 0180, Georgia
    Recruiting
  • Investigational Site Number : 001-301
    Auckland, 0622, New Zealand
    Recruiting
  • Investigational Site Number : 001-801
    Pretoria, 0002, South Africa
    Recruiting
  • Investigational Site Number : 001-803
    Pretoria, 0184, South Africa
    Recruiting
  • Investigational Site Number : 001-804
    Vereeniging, 1935, South Africa
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 50 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 50 months is above that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 17, 2024
StartActual
Mar 27, 2025
Primary completionEst.
Jun 25, 2029
CompletionEst.
Jun 25, 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Georgia
Show 2 added (2 Georgia)
  • Investigational Site Number : 268-003 · Tbilisi, Georgia
  • Investigational Site Number : 268-001 · Tbilisi, Georgia
Oct 21, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Investigational Site Number : 001-201 · Melbourne, AustraliaContact added d•••@alfred.org · •••8592
  • Investigational Site Number : 001-301 · Auckland, New ZealandContact added D•••@momcr.co.nz · •••7669
  • Investigational Site Number : 001-801 · Pretoria, South AfricaContact added h•••@emmed.co.za · •••6844Contact added •••0031
  • Investigational Site Number : 001-803 · Pretoria, South AfricaContact added m•••@bothokebontle.co.za · •••4136
  • Investigational Site Number : 001-804 · Vereeniging, South AfricaContact added c•••@ctcvaal.co.za · •••3958
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    2 sites added — first site in Georgia
    Show 2 added (2 Georgia)
    • Investigational Site Number : 268-003 · Tbilisi, Georgia
    • Investigational Site Number : 268-001 · Tbilisi, Georgia
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Investigational Site Number : 001-201 · Melbourne, AustraliaContact added d•••@alfred.org · •••8592
    • Investigational Site Number : 001-301 · Auckland, New ZealandContact added D•••@momcr.co.nz · •••7669
    • Investigational Site Number : 001-801 · Pretoria, South AfricaContact added h•••@emmed.co.za · •••6844Contact added •••0031
    • Investigational Site Number : 001-803 · Pretoria, South AfricaContact added m•••@bothokebontle.co.za · •••4136
    • Investigational Site Number : 001-804 · Vereeniging, South AfricaContact added c•••@ctcvaal.co.za · •••3958
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06647069
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Mar 27, 2025
Primary completion
Jun 25, 2029 (estimated)
Completion
Jun 25, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6
Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD20 Bispecific Antibody DR-0201

Start the discussion